Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:CSCI - Post Discussion

COSCIENS Biopharma Inc > Market Cap
View:
Post by BoazKhorn on Aug 31, 2024 9:06am

Market Cap

If this entire tird sandwich is worth 20MM then the poor Ceapro suckers who still own shares  have been reduced to about 10MM in value between them. Or another way ,CZO had 77MM shares outstanding at 10MM thats about 0.13 per old CZO share. Luckily for Gilles he has never bought a single share with his own money.  Gilles is hands down the very worst CEO I have ever seen. It's not so much that he is so bad, it's that he is still here, still getting paid after over 2 decades of shareholder destruction.. An incredible story of how a captured board of directors betrays it's shareholders. Lesson learned.
Comment by prophetoffactz on Aug 31, 2024 10:41am
BoazKhorn, "If this entire tird sandwich is worth 20MM then the poor Ceapro suckers who still own shares  have been reduced to about 10MM in value between them." Still amazing to see that someone who follows this company thinks the market should be bidding up the shares when the company has never released any preclinical or clinical data on its avenanthramide pill formulation ...more  
Comment by Hopeforthebest on Aug 31, 2024 10:59am
proph said - "We don't know exactly what the company has but the company has attracted Ronnie Miller " Was that the same NoShowRonnie who was quietly forced out under the guise of early retirement   by his previous company and has now shown that like gagnon no person/company/financial institute want to be part of the scheme? Just asking for a friend.
Comment by prophetoffactz on Aug 31, 2024 11:13am
Perplexity Ai on your post about Ronnie Miller: Based on the information provided in the search results, I can address the factual aspects of your query about Ronnie Miller's retirement from Roche: Ronnie Miller retired from Roche Canada in March 2022 after a long and distinguished career in the pharmaceutical industry. He served as President and CEO of Roche Canada for 22 years ...more  
Comment by Hopeforthebest on Aug 31, 2024 11:41am
Well proph just speaking from experience as every valued executive I have known was always reatined for a period of time to assist with transition and sometimes in other capacities. In addition, everyone of them had a no compete clause in their contract.  By the was your AI really does not say much for a reason does it, kind of useless like the rest of your post.  As for defamatory, I ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities